PL1962886T6 - Stabilne formulacje białkowe - Google Patents

Stabilne formulacje białkowe

Info

Publication number
PL1962886T6
PL1962886T6 PL06846683.8T PL06846683T PL1962886T6 PL 1962886 T6 PL1962886 T6 PL 1962886T6 PL 06846683 T PL06846683 T PL 06846683T PL 1962886 T6 PL1962886 T6 PL 1962886T6
Authority
PL
Poland
Prior art keywords
protein formulations
stable protein
stable
formulations
protein
Prior art date
Application number
PL06846683.8T
Other languages
English (en)
Other versions
PL1962886T3 (pl
Inventor
Manisha M. Dali
Charles E. Dahlheim
Sunita Borsadia
Vijay H. Naringrekar
Rajesh B. Gandhi
Manoj Nerurkar
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1962886(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL1962886T3 publication Critical patent/PL1962886T3/pl
Publication of PL1962886T6 publication Critical patent/PL1962886T6/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL06846683.8T 2005-12-20 2006-12-19 Stabilne formulacje białkowe PL1962886T6 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
PCT/US2006/062297 WO2007076354A2 (en) 2005-12-20 2006-12-19 Stable protein formulations
EP06846683.8A EP1962886B2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Publications (2)

Publication Number Publication Date
PL1962886T3 PL1962886T3 (pl) 2014-03-31
PL1962886T6 true PL1962886T6 (pl) 2023-03-13

Family

ID=38057529

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06846683.8T PL1962886T6 (pl) 2005-12-20 2006-12-19 Stabilne formulacje białkowe

Country Status (24)

Country Link
US (1) US8476239B2 (pl)
EP (1) EP1962886B2 (pl)
JP (2) JP5247467B2 (pl)
KR (1) KR101378194B1 (pl)
CN (3) CN101378773B (pl)
AR (2) AR058567A1 (pl)
AU (1) AU2006330593B2 (pl)
BR (1) BRPI0622256A2 (pl)
CA (1) CA2634547C (pl)
CL (1) CL2010000816A1 (pl)
DK (1) DK1962886T4 (pl)
EA (1) EA014232B1 (pl)
ES (1) ES2436616T5 (pl)
HR (1) HRP20131196T4 (pl)
IL (1) IL192104A (pl)
NO (1) NO347247B1 (pl)
NZ (1) NZ569108A (pl)
PE (1) PE20071063A1 (pl)
PL (1) PL1962886T6 (pl)
PT (1) PT1962886E (pl)
RS (1) RS53127B2 (pl)
SG (1) SG153832A1 (pl)
TW (3) TW200738261A (pl)
WO (1) WO2007076354A2 (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
ES2694000T3 (es) 2008-10-06 2018-12-17 3-D Matrix Ltd. Tapón de tejido
WO2010151212A1 (en) * 2009-06-23 2010-12-29 Ge Healthcare Bio-Sciences Ab Simulator device
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
US20140147418A1 (en) * 2011-04-15 2014-05-29 The Us Of America, As Represented By The Secretary Department Of Health And Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
CA2833623A1 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
HUE043171T2 (hu) 2011-10-07 2019-08-28 Takeda Pharmaceuticals Co Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CN104011073B (zh) 2011-10-18 2017-08-25 科荣生生物科学公司 使用氨基酸稳定的依那西普制剂
EP2867251B1 (en) 2012-06-29 2019-08-21 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
ES2706065T3 (es) 2012-07-06 2019-03-27 3 D Matrix Ltd Proceso de llenado-acabado para soluciones de péptidos
EP2869816A4 (en) * 2012-07-09 2016-04-20 Coherus Biosciences Inc ETANERCEPT FORMULATIONS WITH CLEAR REDUCTION OF SUBVISIBLE PARTICLES
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
DK2890791T3 (da) 2012-08-31 2019-06-11 Us Health Aav-medieret aquaporingenoverførsel til behandling af sjögrens syndrom
AU2013312300A1 (en) 2012-09-07 2015-04-16 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
RS57013B1 (sr) 2012-09-11 2018-05-31 Coherus Biosciences Inc Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
BR112016020584A2 (pt) 2014-03-10 2017-10-03 3 D Matrix Ltd Composições de peptídeo auto-organizável
EA201691634A1 (ru) 2014-03-19 2016-11-30 Бристол-Маерс Сквибб Компани Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
RU2689145C2 (ru) * 2014-04-16 2019-05-24 Биокон Лтд. Стабильные белковые препараты, содержащие молярный избыток сорбитола
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
CN112851790A (zh) 2014-06-23 2021-05-28 诺华股份有限公司 位点特异性蛋白质修饰
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
WO2016080367A1 (ja) 2014-11-18 2016-05-26 塩野義製薬株式会社 安定化されたペプチド組成物
WO2016116842A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
EP3347031B8 (en) * 2015-09-11 2021-04-28 Nutrition & Biosciences USA 1, LLC A composition comprising a protein and a polyalkoxy fatty compound
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
DK3386541T3 (da) 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US11013802B2 (en) 2016-12-07 2021-05-25 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
MA50435A (fr) 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques
IL275499B2 (en) 2017-12-22 2024-03-01 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
CN108014338A (zh) * 2018-01-22 2018-05-11 安徽未名生物医药有限公司 一种注射用巴利昔单抗冻干粉针及其制备方法
WO2019224843A1 (en) * 2018-05-25 2019-11-28 Dr. Reddy's Laboratories Ltd. Ctla4-ig fusion protein formulation
ES3049426T3 (en) * 2018-05-25 2025-12-16 Dr Reddys Laboratories Ltd Stable fusion protein formulation
EP3813791A2 (en) * 2018-06-26 2021-05-05 Lupin Limited Stable lyophilized dosage form of protein
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
SG11202107606VA (en) 2019-01-15 2021-08-30 Inst Nat Sante Rech Med Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
WO2020152367A1 (en) 2019-01-25 2020-07-30 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
IL293367A (en) * 2019-12-20 2022-07-01 Anthos Therapeutics Inc Pharmaceutical formulations and dosage regimens for antibodies to factor xi/xia
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
US20240083970A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy’S Laboratories Limited Compositions comprising fusion protein and analytical attributes thereof
WO2022200442A1 (en) 2021-03-23 2022-09-29 King's College London Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
CN113925963B (zh) * 2021-10-15 2023-08-11 江苏太平洋美诺克生物药业股份有限公司 一种稳定的包含抗cd147单克隆抗体的药物制剂
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
KR20250054810A (ko) * 2022-09-29 2025-04-23 화이자 인코포레이티드 Rsv f 단백질 삼량체를 포함하는 면역원성 조성물
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2025196207A1 (en) 2024-03-20 2025-09-25 King's College London Compositions and methods for use in depleting senescent cells and treating aging
WO2026021575A1 (zh) * 2024-07-26 2026-01-29 鸿运华宁（杭州）生物医药有限公司 一种gipr抗体融合蛋白质的药用稳定溶液制剂及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0686045T3 (da) * 1993-02-23 2001-03-05 Genentech Inc Stabilisering af med organisk opløsningsmiddel behandlede polypeptider med et hjælpestof
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
PT1516628E (pt) * 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
WO2003005465A1 (en) 2001-04-25 2003-01-16 Quallion, Llc Rechargeable lithium battery for tolerating discharge to zero volts
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
DE60237841D1 (de) 2001-11-13 2010-11-11 Genentech Inc Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
DE60335024D1 (de) 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
AU2004264901B2 (en) * 2003-08-04 2009-12-10 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006295340B2 (en) * 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations

Also Published As

Publication number Publication date
CA2634547A1 (en) 2007-07-05
SG153832A1 (en) 2009-07-29
US20100166774A1 (en) 2010-07-01
DK1962886T3 (da) 2014-01-13
ES2436616T5 (es) 2022-05-27
KR101378194B1 (ko) 2014-03-27
TWI393575B (zh) 2013-04-21
BRPI0622256A2 (pt) 2011-08-09
US8476239B2 (en) 2013-07-02
BRPI0620186A2 (pt) 2010-07-06
EP1962886B1 (en) 2013-10-16
CL2010000816A1 (es) 2011-02-11
TW200738261A (en) 2007-10-16
JP5247467B2 (ja) 2013-07-24
EP1962886B2 (en) 2022-02-23
WO2007076354A3 (en) 2007-08-16
NZ569108A (en) 2011-09-30
AR058567A1 (es) 2008-02-13
RS53127B (sr) 2014-06-30
CN101584858A (zh) 2009-11-25
EA014232B1 (ru) 2010-10-29
TW201008595A (en) 2010-03-01
TW201008596A (en) 2010-03-01
AU2006330593B2 (en) 2012-07-26
CN101378773B (zh) 2013-03-13
AU2006330593A1 (en) 2007-07-05
IL192104A0 (en) 2008-12-29
JP2011246470A (ja) 2011-12-08
KR20080078070A (ko) 2008-08-26
EP1962886A2 (en) 2008-09-03
EA200801570A1 (ru) 2008-12-30
CN101378773A (zh) 2009-03-04
IL192104A (en) 2015-01-29
HK1114568A1 (en) 2008-11-07
CN101822820A (zh) 2010-09-08
AR097561A2 (es) 2016-03-23
NO347247B1 (no) 2023-07-31
HRP20131196T4 (hr) 2022-06-10
PE20071063A1 (es) 2007-10-24
HRP20131196T1 (hr) 2014-01-31
NO20082628L (no) 2008-07-15
PT1962886E (pt) 2014-01-07
CA2634547C (en) 2016-10-11
JP2009524595A (ja) 2009-07-02
WO2007076354A2 (en) 2007-07-05
JP5538309B2 (ja) 2014-07-02
PL1962886T3 (pl) 2014-03-31
DK1962886T4 (da) 2022-05-02
ES2436616T3 (es) 2014-01-03
RS53127B2 (sr) 2022-06-30

Similar Documents

Publication Publication Date Title
IL192104A0 (en) Stable protein formulations
GB2424581B (en) Formulations
EP1988922A4 (en) PROTEIN FORMULATIONS
ZA200800338B (en) Self-buffering protein formulations
IL185773A0 (en) Formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
IL192149A0 (en) Stable s-nitrosothiol formulations
EP1951693A4 (en) SOLID FORMULATIONS
GB0514482D0 (en) Protein
SI1962886T2 (sl) Stabilne proteinske formulacije
IL179208A0 (en) Intereferon formulations
GB0511861D0 (en) Proteins
GB0513653D0 (en) Protein stability
GB0520388D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0526322D0 (en) Formulations
GB0522917D0 (en) Formulations
GB0500915D0 (en) Novel formulations
GB0519090D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0504106D0 (en) Novel formulations
GB0500912D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0516302D0 (en) Protein